Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders
Standard
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders. / Konen, Franz Felix; Möhn, Nora; Witte, Torsten; Schefzyk, Matthias; Wiestler, Miriam; Lovric, Svjetlana; Hufendiek, Karsten; Schwenkenbecher, Philipp; Sühs, Kurt-Wolfram; Friese, Manuel A; Klotz, Luisa; Pul, Refik; Pawlitzki, Marc; Hagin, David; Kleinschnitz, Christoph; Meuth, Sven G; Skripuletz, Thomas.
in: AUTOIMMUN REV, Jahrgang 22, Nr. 5, 05.2023, S. 103312.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders
AU - Konen, Franz Felix
AU - Möhn, Nora
AU - Witte, Torsten
AU - Schefzyk, Matthias
AU - Wiestler, Miriam
AU - Lovric, Svjetlana
AU - Hufendiek, Karsten
AU - Schwenkenbecher, Philipp
AU - Sühs, Kurt-Wolfram
AU - Friese, Manuel A
AU - Klotz, Luisa
AU - Pul, Refik
AU - Pawlitzki, Marc
AU - Hagin, David
AU - Kleinschnitz, Christoph
AU - Meuth, Sven G
AU - Skripuletz, Thomas
N1 - Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2023/5
Y1 - 2023/5
N2 - More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) and new therapeutic options are on the horizon. Due to different underlying therapeutic mechanisms, a more individualized selection of DMTs in MS is possible, taking into account the patient's current situation. Therefore, concomitant treatment of various comorbid conditions, including autoimmune mediated disorders such as rheumatoid arthritis, should be considered in MS patients. Because the pathomechanisms of autoimmunity partially overlap, DMT could also treat concomitant inflammatory diseases and simplify the patient's treatment. In contrast, the exacerbation and even new occurrence of several autoimmune diseases have been reported as a result of immunomodulatory treatment of MS. To simplify treatment and avoid disease exacerbation, knowledge of the beneficial and adverse effects of DMT in other autoimmune disorders is critical. Therefore, we conducted a literature search and described the beneficial and adverse effects of approved and currently studied DMT in a large number of comorbid autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, cutaneous disorders including psoriasis, Sjögren´s syndrome, systemic lupus erythematosus, systemic vasculitis, autoimmune hepatitis, and ocular autoimmune disorders. Our review aims to facilitate the selection of an appropriate DMT in patients with MS and comorbid autoimmune diseases.
AB - More than 10 disease-modifying therapies (DMT) are approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple sclerosis (MS) and new therapeutic options are on the horizon. Due to different underlying therapeutic mechanisms, a more individualized selection of DMTs in MS is possible, taking into account the patient's current situation. Therefore, concomitant treatment of various comorbid conditions, including autoimmune mediated disorders such as rheumatoid arthritis, should be considered in MS patients. Because the pathomechanisms of autoimmunity partially overlap, DMT could also treat concomitant inflammatory diseases and simplify the patient's treatment. In contrast, the exacerbation and even new occurrence of several autoimmune diseases have been reported as a result of immunomodulatory treatment of MS. To simplify treatment and avoid disease exacerbation, knowledge of the beneficial and adverse effects of DMT in other autoimmune disorders is critical. Therefore, we conducted a literature search and described the beneficial and adverse effects of approved and currently studied DMT in a large number of comorbid autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, cutaneous disorders including psoriasis, Sjögren´s syndrome, systemic lupus erythematosus, systemic vasculitis, autoimmune hepatitis, and ocular autoimmune disorders. Our review aims to facilitate the selection of an appropriate DMT in patients with MS and comorbid autoimmune diseases.
U2 - 10.1016/j.autrev.2023.103312
DO - 10.1016/j.autrev.2023.103312
M3 - SCORING: Review article
C2 - 36924922
VL - 22
SP - 103312
JO - AUTOIMMUN REV
JF - AUTOIMMUN REV
SN - 1568-9972
IS - 5
ER -